share_log

10-Q/A: Quarterly report (Amendment)

10-Q/A: Quarterly report (Amendment)

10-Q/A:季度報表(修正版)
美股SEC公告 ·  2024/11/15 06:28

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals reported a net loss of $5.4 million for Q2 2024, compared to a $1.7 million loss in Q2 2023. Revenue remained at zero while operating expenses increased to $3.1 million, primarily driven by higher general and administrative costs. Research and development expenses were $25,000 for the quarter as the company focused on developing co-crystals of AZD1656.The company significantly expanded its pipeline through a major licensing agreement with AstraZeneca in August 2024, gaining exclusive rights to HK-4 Glucokinase activators AZD1656 and AZD5658 for all indications, as well as myeloperoxidase inhibitor AZD5904 for male infertility treatment. As consideration, Conduit issued 9.5 million shares to AstraZeneca and paid a $1.5 million upfront fee.As of June 30, 2024, Conduit had cash and cash equivalents of $0.2 million, down from $4.2 million at year-end 2023. The company secured additional funding through a $2.65 million senior secured note in August 2024 but noted substantial doubt about its ability to continue as a going concern without raising additional capital. Management is pursuing various financing options including public or private equity/debt offerings.
Conduit Pharmaceuticals reported a net loss of $5.4 million for Q2 2024, compared to a $1.7 million loss in Q2 2023. Revenue remained at zero while operating expenses increased to $3.1 million, primarily driven by higher general and administrative costs. Research and development expenses were $25,000 for the quarter as the company focused on developing co-crystals of AZD1656.The company significantly expanded its pipeline through a major licensing agreement with AstraZeneca in August 2024, gaining exclusive rights to HK-4 Glucokinase activators AZD1656 and AZD5658 for all indications, as well as myeloperoxidase inhibitor AZD5904 for male infertility treatment. As consideration, Conduit issued 9.5 million shares to AstraZeneca and paid a $1.5 million upfront fee.As of June 30, 2024, Conduit had cash and cash equivalents of $0.2 million, down from $4.2 million at year-end 2023. The company secured additional funding through a $2.65 million senior secured note in August 2024 but noted substantial doubt about its ability to continue as a going concern without raising additional capital. Management is pursuing various financing options including public or private equity/debt offerings.
Conduit Pharmaceuticals 在2024年第二季度報告淨虧損540萬美元,而2023年第二季度虧損爲170萬美元。營業收入保持爲零,而營業費用增加至310萬美元,主要是由於一般和管理費用的增加。研究和開發費用在本季度爲25,000美元,因爲公司專注於開發AZD1656的共結晶。該公司通過與阿斯利康在2024年8月簽署的一項重大許可協議,顯著擴大了其產品管線,獲得了Hk-4糖激酶激活劑AZD1656和AZD5658在所有適應症上的獨佔權,以及用於男性不育治療的髓過氧化物酶抑制劑AZD5904。作爲對價,Conduit向阿斯利康發行了950萬股股份,並支付了150萬美元的預付費。展開全部
Conduit Pharmaceuticals 在2024年第二季度報告淨虧損540萬美元,而2023年第二季度虧損爲170萬美元。營業收入保持爲零,而營業費用增加至310萬美元,主要是由於一般和管理費用的增加。研究和開發費用在本季度爲25,000美元,因爲公司專注於開發AZD1656的共結晶。該公司通過與阿斯利康在2024年8月簽署的一項重大許可協議,顯著擴大了其產品管線,獲得了Hk-4糖激酶激活劑AZD1656和AZD5658在所有適應症上的獨佔權,以及用於男性不育治療的髓過氧化物酶抑制劑AZD5904。作爲對價,Conduit向阿斯利康發行了950萬股股份,並支付了150萬美元的預付費。截至2024年6月30日,Conduit的現金及現金等價物爲20萬美元,低於2023年底的420萬美元。公司通過在2024年8月發行265萬美元的高級擔保票據獲得了額外資金,但指出在沒有募集額外資本的情況下,持續經營能力存在重大疑慮。管理層正在尋求各種融資選擇,包括公共或股權投資/債務發行。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息